Beth established her contract research consulting company in 1999. Throughout her long career, she has provided operational oversight for early and late phase programs for Fortune 500 companies, including global submissions of blockbuster products. Beth has contributed to advancements in a multitude of therapeutic areas, including oncology, CNS, and clinical pharmacology.
In 2015, Beth expanded and renamed her company to Trialwise, a boutique CRO specializing in early phase studies. As the founder and president of Trialwise, Beth oversees a skilled team conducting clinical research for Phase 1 and 2 studies from planning through execution, and regularly consults with select private and government clients. Her expertise includes the complexities of data sources and their interface with clinical databases, data monitoring, the CRO landscape, and Good Clinical Practice.
Beth studied psychology and zoology at Brigham Young University and holds an MBA from the C.T. Bauer College of Business at the University of Houston.